Clincosm LogoSign in Get a demo

Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT Study

Sponsor
Thomas Jefferson University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04789018
Collaborator
(none)
200
Enrollment
1
Location
65.1
Anticipated Duration (Months)
3.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.

Condition or Disease Intervention/Treatment Phase
  • Other: Educational Intervention
  • Other: Survey Administration
  • Other: Interview

Detailed Description

PRIMARY OBJECTIVE:
  1. To assess perceived usefulness of a virtual genetics board.
SECONDARY OBJECTIVE:
  1. To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge.
OUTLINE:

Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology ENGAGEMENT Study (Virtual Genetics Board)
Actual Study Start Date :
Jan 21, 2020
Anticipated Primary Completion Date :
Jun 25, 2025
Anticipated Study Completion Date :
Jun 25, 2025

Arms and Interventions

Arm Intervention/Treatment
Observational (survey, virtual genetic board, interview)

Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

Other: Educational Intervention
Attend virtual genetics board
Other Names:
  • Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

    • Other: Survey Administration
    Complete survey

    Other: Interview
    Complete interview

    Outcome Measures

    Primary Outcome Measures

    1. Mean Likert scaled perceived usefulness scores of the virtual genetics board [After virtual genetics board]

      Perceived usefulness will be judged against a benchmark mean score of 5/7.

    Secondary Outcome Measures

    1. Means or changes in means of Likert scaled acceptability/feasibility [Before and after virtual genetics board]

      Will be summarized by means, standard deviations, and 95% confidence intervals.

    2. Perceived ease of use [After virtual genetics board]

      Will be summarized by means, standard deviations, and 95% confidence intervals.

    3. Self-efficacy for recommendations [Before and after virtual genetics board]

      Will be summarized by means, standard deviations, and 95% confidence intervals.

    4. Change in mean scores on 17 genetics knowledge test questions [Baseline up to post-virtual genetics board]

      Will be summarized by means, standard deviations, and 95% confidence intervals.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Non-genetic providers who perform PCA genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)

    Exclusion Criteria:

    • Non-medical providers

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia Pennsylvania United States 19107

    Sponsors and Collaborators

    • Thomas Jefferson University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Thomas Jefferson University
    ClinicalTrials.gov Identifier:
    NCT04789018
    Other Study ID Numbers:
    • 20F.936
    First Posted:
    Mar 9, 2021
    Last Update Posted:
    Mar 9, 2021
    Last Verified:
    Mar 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Prostatic Neoplasms

    Study Results

    No Results Posted as of Mar 9, 2021